Results 151 to 160 of about 19,127 (267)

Gallbladder Myeloid Sarcoma Associated With NPM1 Mutated Acute Myeloid Leukemia

open access: yes
eJHaem, Volume 6, Issue 4, August 2025.
Francesco Grimaldi   +5 more
wiley   +1 more source

IgG4‐Related Disease Mimicking Metastatic Malignancy: Polyserositis and Abdominal Lymphadenopathy

open access: yesClinical Case Reports, Volume 13, Issue 7, July 2025.
ABSTRACT In patients presenting with multiple space‐occupying lesions, preserved general condition, and normal or mildly elevated tumor markers, IgG4‐related disease (IgG4‐RD) should be considered in the differential diagnosis. We report an extremely unusual case of IgG4‐RD mimicking metastatic malignancy, with polyserositis and widespread abdominal ...
Meisi Huo   +3 more
wiley   +1 more source

Aggressive Myeloid Sarcoma Mimicking Burkitt's Lymphoma

open access: yes
eJHaem, Volume 6, Issue 4, August 2025.
Eman Hassan   +4 more
wiley   +1 more source

Economic Burden of Obesity in Iran University of Medical Sciences: A Cost Analysis Using the Cost of Illness Framework

open access: yesHealth Science Reports, Volume 8, Issue 7, July 2025.
ABSTRACT Background and Aims Obesity is a multifaceted health issue that significantly elevates the risk of various chronic diseases and can lead to a reduction in life expectancy by 5–20 years. This study aimed to estimate both the direct and indirect costs associated with obesity among the population served by Iran University of Medical Sciences in ...
Mahmoud Zamandi   +3 more
wiley   +1 more source

The impact of the novel EUS scope and ultrasonographic system for diagnosis and therapy in patients with pancreatobiliary diseases (videos)

open access: yesJournal of Hepato-Biliary-Pancreatic Sciences, Volume 32, Issue 7, Page 544-553, July 2025.
Kojima and colleagues evaluated the diagnostic and therapeutic performance of advanced endoscopic ultrasonography in pancreaticobiliary diseases using novel scopes and imaging techniques such as detective flow imaging and shear wave elastography. These innovations achieved high technical and clinical success rates, enhancing safety and diagnostic ...
Hiroyuki Kojima   +9 more
wiley   +1 more source

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

open access: yesMedComm, Volume 6, Issue 7, July 2025.
CVL218, a PARP1/2 inhibitor, was generally well tolerated and safe in solid tumors. It showed potential antitumor activity in patients treated with the recommended dose (700 mg BID). ABSTRACT CVL218, a novel poly ADP‐ribose polymerase (PARP1/2) inhibitor, has strong PARP1/2 selective inhibitory activity and high oral bioavailability. We aimed to assess
Zihong Chen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy